India’s Biopharma Export Story: How “Pharmacy of the World” Is Evolving 

Relevant Global and Market Data 

India’s biopharmaceutical export story is one of remarkable transformation. From being a net importer of medicines in the late 20th century to becoming the “pharmacy of the world”, India now plays a central role in global health supply chains. This evolution reflects decades of manufacturing excellence, strategic policy support, and an ability to supply quality medicines at competitive costs. 

In this blog, we explore how India’s biopharma exports have expanded, the forces behind this growth, the emerging shifts in product mix, and what the future might hold. 

A Snapshot of India’s Export Strength 

India has built an extensive global footprint in pharmaceuticals: 

• India supplies around 20% of global demand for generic medicines and is a major vaccine manufacturer for worldwide immunization programmes. 

• Indian pharmaceutical exports reached approximately US$30.4 billion in FY2024-25, showing strong year-on-year growth. 

• These exports span formulations, biologicals, APIs, and bulk drugs, with formulations and biologics making up about 79% of the export mix. 

• Indian drugs and vaccines are exported to more than 200 countries, including major regulated markets in North America and Europe. 

This scale — both by volume and geographic reach — underscores India’s critical role in ensuring global access to affordable medicines. Building trust through compliance with international quality standards, including approvals from regulators such as the US FDA and WHO GMP, has been central to this success. 

Drivers Behind Export Growth 

1. Cost Competitiveness and Manufacturing Scale 

One of India’s defining advantages is its manufacturing scale coupled with cost competitiveness. Indian facilities produce high volumes of quality generics and vaccines at significantly lower costs than many competitor nations, enabling global buyers to procure medicines at more accessible price points. 

India’s vast base of US FDA- and WHO GMP-compliant plants — among the highest outside the United States — further enhances export credibility. 

2. Diverse Product Portfolio 

The export basket has expanded beyond generic small-molecule drugs to include more biological products, vaccines, and complex formulations. In recent years, this shift has accelerated as global demand rises for biologics and biosimilars alongside traditional products. 

Vaccines, in particular, represent a significant share of India’s export strength; India produces a majority of the world’s DPT, BCG, and measles vaccines. 

3. Global Health & Geopolitical Demand 

India’s biopharma exports play a strategic role in global health. Low- and middle-income countries, especially in Africa and Southeast Asia, rely on Indian medicines to meet public health needs cost-effectively. The COVID-19 pandemic further demonstrated India’s capacity to supply essential vaccines and therapeutics at scale. 

Shifting Narrative: From Volume to Value 

Despite strong export performance by volume, India’s export value ranking (currently outside the top five globally) shows room for growth. According to industry forecasts, strategic shifts toward higher-value segments such as specialty generics, biosimilars, and novel biologics could reshape India’s export profile in the years ahead. 

Long-term projections suggest that: 

• Total pharmaceutical exports could grow to US$65 billion by 2030 and reach US$350 billion by 2047 with targeted investments and policy support. 

• Biosimilar exports, currently a modest share, could grow five-fold by 2030 and capture meaningful global market share, driven by an expanded pipeline and capacity build-out. 

This transition from a primarily volume-based exporter to a value-led innovator and exporter would elevate India’s global position and resilience. 

Challenges and Future Outlook 

India’s export success is not without challenges: 

• Competing in highly regulated markets requires sustained compliance with evolving quality norms and intellectual property considerations. 

• Diversifying beyond traditional generics into specialty and high-value products requires increased R&D investments, skilled talent, and supportive regulatory frameworks. 

At the same time, global demand for affordable healthcare continues to rise, creating opportunities for Indian biopharma manufacturers and exporters. Emerging markets in Latin America, Africa, and parts of Asia are becoming increasingly important destinations. Strategic trade partnerships and export facilitation policies can support deeper market penetration. 

Conclusion 

India’s evolution as the pharmacy of the world reflects decades of industrial capability, policy support, and global engagement. With exports worth over US$30 billion today, and projections targeting transformative growth in higher-value segments, the Indian biopharma export story is entering a new chapter. Sustained focus on quality, innovative product development, and global diversification could enable India not only to maintain its foundational role in supplying affordable medicines but also to lead in advanced biopharmaceutical exports in the decades ahead.